Search research articles
Contact Us
Filters
Showing results (51-60 of 237) with videos related to
Page
of 24
Sort By:
Clinical Pharmacology and Therapeutics
|
January 1, 1994
Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects
K E Mörike, D M Roden
American Heart Journal
|
February 1, 1985
QT prolongation and arrhythmia suppression
D M Roden, R L Woosley
Clinical Pharmacology and Therapeutics
|
December 16, 2015
Integrating electronic health record genotype and phenotype datasets to transform patient care
D M Roden, J C Denny
Medical Toxicology and Adverse Drug Experience
|
November 1, 1989
A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs?
F A Fish, D M Roden
The American Journal of Cardiology
|
April 30, 1987
Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs
R L Woosley, D M Roden
The American Journal of Medicine
|
March 20, 1987
Effects of low potassium or magnesium concentrations on isolated cardiac tissue
D M Roden, D H Iansmith
Handbook of Experimental Pharmacology
|
April 14, 2006
Proarrhythmia
D M Roden, M E Anderson
Clinical Pharmacology and Therapeutics
|
July 23, 2013
Genomic medicine, precision medicine, personalized medicine: what's in a name?
D M Roden, R F Tyndale
Heart (British Cardiac Society)
|
August 24, 2000
The pause that refreshes, or does it? Mechanisms in torsades de pointes
D M Roden, M E Anderson
Cardiovascular Research
|
February 26, 2000
A plethora of mechanisms in the HERG-related long QT syndrome. Genetics meets electrophysiology
D M Roden, J R Balser
Page
of 24
Search research articles
Search
Showing results (51-60 of 237) with videos related to
Sort By:
Page
of 24
Clinical Pharmacology and Therapeutics
|
January 1, 1994
Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects
K E Mörike, D M Roden
American Heart Journal
|
February 1, 1985
QT prolongation and arrhythmia suppression
D M Roden, R L Woosley
Clinical Pharmacology and Therapeutics
|
December 16, 2015
Integrating electronic health record genotype and phenotype datasets to transform patient care
D M Roden, J C Denny
Medical Toxicology and Adverse Drug Experience
|
November 1, 1989
A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs?
F A Fish, D M Roden
The American Journal of Cardiology
|
April 30, 1987
Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs
R L Woosley, D M Roden
The American Journal of Medicine
|
March 20, 1987
Effects of low potassium or magnesium concentrations on isolated cardiac tissue
D M Roden, D H Iansmith
Handbook of Experimental Pharmacology
|
April 14, 2006
Proarrhythmia
D M Roden, M E Anderson
Clinical Pharmacology and Therapeutics
|
July 23, 2013
Genomic medicine, precision medicine, personalized medicine: what's in a name?
D M Roden, R F Tyndale
Heart (British Cardiac Society)
|
August 24, 2000
The pause that refreshes, or does it? Mechanisms in torsades de pointes
D M Roden, M E Anderson
Cardiovascular Research
|
February 26, 2000
A plethora of mechanisms in the HERG-related long QT syndrome. Genetics meets electrophysiology
D M Roden, J R Balser
Page
of 24